外科理论与实践Issue(1)：61-65,5.DOI:10.16139/j.1007-9610.2016.01.014
TOPOⅠ表达和K-ras基因突变在转移性结肠直肠癌个体化治疗中的价值
Clinical values of topoisomeraseⅠexpression and K-ras gene mutation in individualized therapies of metastatic ;colorectal cancer
肖立俊 1曹奕鸥 1李东华 1刘绍群 1雷铭 1茅安炜 1苏畅1
作者信息
- 1. 上海市闵行区中心医院胃肠外科，上海 201100
- 折叠
摘要
Abstract
Objective To study the clinical values of detecting topoisomerase Ⅰ(TOPOⅠ) expression and K-ras gene mutation in individualized therapies of metastatic colorectal cancer. Methods Forty patients with radical resection and postoperational metastatic colorectal cancer were randomised into 2 groups from January 2012 to June 2014 in this hospi-tal. The patients in test group received individualized treatment following TOPOⅠexpression and K-ras gene mutation while the patients in control group had randomized treatment. The clinical efficacy and adverse reactions were observed. Objective response rate (ORR) and disease control rate (DCR) were evaluated and the survival was analyzed by Kaplan-Meier method. Results Thirty-nine patients could be evaluated. ORR and DCR were 67%and 81%in test group and 50%and 72% in control group respectively. There was no significant differences between two groups (P>0.05). Frequency of erythra in test group was higher than that in control group while test group had lower frequency of diarrhea (P<0.05). Median progression free survival was 8 months for test group and 5 months for control group (P<0.05 ), while median sur-vival times was 16 months for test group and 13 months for control group respectively (P>0.05). Conclusions The indivi-dualized treatment based on detection of TOPOⅠexpression and K-ras gene can delay progress of disease, reduce adverse reactions and have some effect in metastatic colorectal cancer.关键词
结肠直肠癌/肿瘤转移/药物疗法/个体化治疗Key words
Colorectal cancer/Neoplasms metastasis/Drug therapy/Individualized treatment分类
医药卫生引用本文复制引用
肖立俊,曹奕鸥,李东华,刘绍群,雷铭,茅安炜,苏畅..TOPOⅠ表达和K-ras基因突变在转移性结肠直肠癌个体化治疗中的价值[J].外科理论与实践,2016,(1):61-65,5.
